查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2016220

即时检测市场：2026-2032年全球市场预测（按产品类型、检测类型、检体类型、技术、便携性、购买方式、应用、最终用户和分销管道划分）

Point of Care Testing Market by Product, Test Type, Sample Type, Technology, Portability, Mode of Purchase, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，即时检测市场价值将达到 371.3 亿美元，到 2026 年将成长至 419.9 亿美元，到 2032 年将达到 907.6 亿美元，年复合成长率为 13.61%。

主要市场统计数据
基准年 2025 371.3亿美元
预计年份：2026年 419.9亿美元
预测年份 2032 907.6亿美元
复合年增长率 (%) 13.61%

该行业概览清楚地说明了分散式诊断、先进检测和数位融合如何重新定义临床决策过程。

即时检测（POC​​T）透过让患者更方便地获得及时的临床决策，持续革新着我们的诊断方式。本文概述了当前即时检测生态系统的现状，重点关注分散式诊断、数位化连接和治疗决策支援的融合。随着医疗系统优先考虑快速分流、价值导向医疗和门诊管理，即时检测因其能够减少临床延误并改善患者体验而日益受到重视。

多参数检测、互联互通和医疗保健服务模式的进步如何融合起来，从而为分散式诊断实践带来系统性变革？

在技​​术、医疗服务模式和患者期望的共同驱动下，即时检测领域正经历着一场变革。首先，技术进步正推动检测方式从快速单项分析转向多参数检测平台和整合分子诊断工作流程，从而拓展了现场诊断的范围。同时，感测器的微型化和微流体技术的整合正在减少检体用量和检测时间，提高了居家和门诊环境下应用的可行性。

评估美国于 2025 年推出的关税措施对即时检测相关人员的多方面营运和供应链影响。

美国2025年实施的关税和贸易措施对即时检测产业的製造商、供应商和终端用户产生了复杂的影响。零件、耗材和成品的关税推高了依赖全球供应链的产品总成本，可能影响筹资策略和补货频率。由于许多仪器和试剂都包含来自多个地区的电子元件、塑胶和精密加工零件，因此关税导致的成本增加往往不均衡，并且取决于特定子组件的产地。

我们透过综合細項分析来支援策略规划，整合了产品、技术、测试类型、便携性、购买方式、应用、最终用户、检体类型和分销管道的趋势。

细分洞察揭示了各个产品类型、测试类型、检体基质、技术、便携性选项、购买方式、应用、最终用户和分销管道如何塑造需求模式和发展重点。在产品细分中，耗材、服务和软体、仪器和分析仪以及试剂和检测方法各自具有不同的意义。耗材、配件、维护和校准服务以及软体和连接性支援持续的收入来源和营运连续性。桌上型分析仪、分子诊断平台、可携式分析仪和读数器/扫描仪决定了部署方案和临床工作流程。同时，血糖试纸、血液检测试剂、免疫检测试剂、横向流动化验试剂和分子诊断试剂盒驱动特定检测方法的供应链和品质保证要求。

美洲、欧洲、中东和非洲以及亚太地区的地理差异如何影响照护现场的采购、监管和实施？

细微的区域差异显着影响着就地检验的设计、实施和报销方式，美洲、欧洲、中东、非洲和亚太地区各自拥有独特的市场驱动因素和营运考量。在美洲，医疗保健系统优先考虑门诊优化和慢性病管理，因此对支持远端监测以及在诊所和家庭环境中快速进行心血管和代谢检测的设备和检测方法的需求日益增长。该地区的经销网络优先考虑整合的供应链和本地化的服务支持，这使得能够证明其拥有强大的售后服务以及与主流电子健康记录系统数据互通性的製造商更具优势。

策略性竞争行动和以平台为中心的创新决定了诊断生态系统的准备度、韧性和长期差异化。

即时检测 (POCT) 领域的竞争格局以策略伙伴关係、平台差异化以及对整合仪器、耗材和软体的整合解决方案的重视为特征。主要企业优先考虑支援多种检测形式的模组化平台架构，从而实现快速部署，并透过对耗材的持续需求提升产品生命週期价值。同时，与连接供应商和医疗 IT 整合商的合作对于提供可整合到临床工作流程和社区健康促进倡议的数据丰富的诊断结果至关重要。

企业应实施切实可行的、高优先顺序的策略措施，以确保诊断领域的应用、供应弹性和可持续的商业性差异化。

为保持竞争力和临床意义，产业领导企业应推动一系列务实倡议，使产品开发与实际营运状况和不断发展的医疗模式相契合。首先，应优先考虑互通性和以使用者为中心的软体设计，确保仪器能够无缝整合到临床医生的工作流程和电子健康记录中，从而降低部署门槛。其次，应投资于模组化平台策略，以实现检测的快速扩展和对多种检体类型的支持，从而提高采购团队的柔软性，并减少部署多台仪器的需求。

采用透明且可重复的研究途径，结合对关键相关人员的访谈、严格的二手文献综述和资料三角验证，以检验结论。

本分析的调查方法融合了定性和定量方法，旨在确保研究的严谨性、相关性和可重复性。主要研究工作包括对医疗专业人员、实验室负责人以及设备製造商和分销商的高级管理人员进行深入访谈，以了解实际应用案例、采购限制和尚未解决的需求。此外，也辅以现场观察和工作流程整合点的检验，将临床优先事项转化为产品需求。

一项旨在实现快速诊断、营运弹性和严格品管之间平衡的最终整合方案，以产生临床影响。

总之，即时检测正处于转折点，由于技术成熟、医疗服务模式的变革和政策的调整，诊断路径正在重新定义。检测化学、仪器小型化和软体连接性的进步推动了去中心化诊断的普及，但这种转变也带来了营运、监管和供应链方面的挑战，需要认真考虑。关税措施、采购优先事项的转变以及区域监管差异进一步增加了复杂性，相关人员必须透过弹性采购、适应性强的产品架构和可靠的证据来应对这些挑战。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 即时检测市场：依产品划分

  • 耗材、服务和软体
    • 耗材和配件
    • 维护和校准
    • 软体和连接功能
  • 仪器/分析仪
    • 桌上型分析仪
    • 分子诊断平台
    • 可携式分析仪
    • 阅读器和扫描仪
  • 试剂和测定
    • 血糖试纸
    • 血液检测试剂
    • 免疫检测试剂
    • 横向流动化验试剂
    • 分子诊断试剂盒

第九章 依检测类型分類的即时检测市场

  • 血气分析
  • 心臟标记物
    • B型钠尿肽
    • 肌钙蛋白
  • 综合代谢指标
  • 药物滥用检测
  • 血液学
    • 血液凝固检验
      • 活化部份凝血活酵素时间
      • 纤维蛋白原水平
      • 凝血酶原时间与国际标准化比值
    • 血液常规检查
  • 感染疾病
    • 胃肠道传染病检查
    • 呼吸道传染病检查
    • 性行为感染感染检测
  • 分子诊断
  • 怀孕与不孕
  • 尿液检查

第十章 依检体类型分類的即时侦测市场

  • 血
  • 鼻腔和棉花棒检体
  • 唾液
  • 尿

第十一章 即时侦测市场：依技术划分

  • 生物感测器（电化学公式）
  • 比色平台
  • 免疫检测
  • 横向流动化验
    • 抗体检测
    • 抗原检测
    • 多侧向流
  • 微流体技术
  • PCR和分子诊断

第十二章 即时检测市场：便携式

  • 固定式分析仪
  • 携带式手持设备

第十三章 依购买方式分類的即时侦测市场

  • 市售检测套组
  • 处方笺处方检测

第十四章 即时检测市场：依应用领域划分

  • 慢性病管理
  • 急诊/重症监护
  • 感染疾病诊断
  • 职业和职场测试
  • 肿瘤监测
  • 女性健康

第十五章 即时检测市场：依最终用户划分

  • 门诊部
  • 诊断检查室
  • 独立急诊科
  • 居家照护
  • 医院和诊所
  • 急诊中心

第十六章 即时侦测市场：依通路划分

  • 离线
    • 直销
    • 销售代理商和批发商
    • 零售和药房
  • 在线的

第十七章 即时检测市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十八章 即时侦测市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十九章 即时侦测市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第二十章：美国即时检测市场

第21章：中国的即时检测市场

第22章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abaxis, Inc. by Zoetis Inc
  • Abbott Laboratories
  • AccuBioTech Co., Ltd.
  • ACON Laboratories, Inc.
  • Beckman Coulter
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • CardioGenics Holdings Inc.
  • Chembio Diagnostic Systems, Inc. by Biosynex
  • Danaher Corporation
  • EKF Diagnostics Holdings
  • F. Hoffmann-La Roche Ltd
  • GE Healthcare Technologies, Inc.
  • Medtronic Plc
  • Nova Biomedical Corporation
  • OraSure Technologies, Inc.
  • Quidel Corporation
  • Radiometer Medical ApS
  • Randox Laboratories Ltd.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-035AB9C0DA8B

The Point of Care Testing Market was valued at USD 37.13 billion in 2025 and is projected to grow to USD 41.99 billion in 2026, with a CAGR of 13.61%, reaching USD 90.76 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 37.13 billion
Estimated Year [2026] USD 41.99 billion
Forecast Year [2032] USD 90.76 billion
CAGR (%) 13.61%

A clear industry introduction highlighting how decentralized diagnostics, advanced assays, and digital convergence are redefining clinical decision pathways

Point of care testing continues to reshape diagnostics by bringing timely clinical decision-making closer to the patient. This introduction outlines the contemporary contours of the point of care testing ecosystem, emphasizing the convergence of decentralized diagnostics, digital connectivity, and therapeutic decision support. As health systems prioritize faster triage, value-based care, and outpatient management, point of care modalities are increasingly evaluated for their capacity to reduce clinical latency and improve patient experience.

Advances in miniaturized instrumentation, assay chemistry, and molecular methods now permit a broader range of analytes to be tested outside central laboratories. At the same time, software and connectivity tools are maturing to facilitate result integration with electronic health records and telehealth workflows. These developments are encouraging new use cases within emergency care, chronic disease monitoring, and community screening programs. Consequently, stakeholders across the value chain are recalibrating product development, reimbursement strategies, and distribution models to support rapid adoption while ensuring quality and regulatory compliance.

How converging advances in multiplexed assays, connectivity, and care delivery models are driving systemic change in decentralized diagnostic practice

The landscape of point of care testing is undergoing transformative shifts driven by technology, care delivery models, and patient expectations. First, the technological trajectory is moving from single-analyte rapid tests toward multiplexed platforms and integrated molecular workflows, enabling broader diagnostic breadth at the point of need. Concurrently, sensor miniaturization and microfluidic integration are reducing sample volume and turnaround time, which enhances feasibility for home and ambulatory environments.

Second, care delivery models are evolving: outpatient and community settings are absorbing responsibilities historically held by centralized laboratories, and telemedicine interfaces increasingly rely on near-real-time diagnostics to inform remote consultations. Third, the role of software and connectivity has intensified, with interoperability and cybersecurity becoming prerequisites for clinical adoption. Regulatory pathways are also adapting to accommodate decentralized diagnostics, creating opportunities as well as expectations for robust quality management systems. Finally, patient-centric trends-such as convenience, rapid reassurance, and longitudinal monitoring-are reshaping product design priorities, emphasizing user experience, simplified workflows, and clear result interpretation. Together, these shifts are not incremental but collectively redefine procurement decisions, clinical pathways, and competitive positioning across the ecosystem.

Assessing the multifaceted operational and supply chain consequences of United States tariff measures introduced in 2025 on point of care testing stakeholders

The imposition of tariffs and trade measures by the United States in 2025 introduces a complex set of effects for manufacturers, suppliers, and end users in the point of care testing space. Tariffs on components, consumables, and finished devices can elevate landed costs for products that rely on global supply chains, thereby influencing procurement strategies and reorder cadence. Since many instruments and reagents incorporate electronic components, plastics, and precision machined parts sourced from multiple geographies, tariff-driven cost escalation tends to be uneven and dependent on the origin of specific subcomponents.

In response to tariff pressures, manufacturers may accelerate regional sourcing strategies, increase vertical integration of critical elements, or relocate certain production activities to tariff-favored jurisdictions. These operational adjustments can mitigate exposure but often require near-term capital and redesign efforts. For healthcare providers and distributors, the cumulative effect of tariffs can shift purchasing towards products with more stable supply chain footprints, local assembly, or alternative suppliers offering comparable clinical performance. Pricing adjustments may also influence inventory policies, with stakeholders maintaining higher safety stocks to buffer against potential re-pricing or delays. Importantly, the regulatory and quality assurance implications of sourcing changes necessitate careful validation to ensure clinical equivalence, so organizations must balance cost-containment with the need to preserve test accuracy and continuity of care.

Comprehensive segmentation analysis uniting product, technology, test type, portability, purchase mode, application, end user, sample type, and distribution channel dynamics to inform strategy

Segmentation insights reveal how distinct product categories, test types, sample matrices, technologies, portability options, purchase modes, applications, end users, and distribution channels shape demand patterns and development priorities. Within product segmentation, consumables, services and software, instruments and analyzers, and reagents and assays each carry discrete implications: consumables, accessories and service maintenance and calibration, and software and connectivity underpin ongoing revenue streams and operational continuity; benchtop analyzers, molecular platforms, portable analyzers, and readers and scanners determine deployment scenarios and clinical workflows; while glucose test strips, hematology reagents, immunoassay reagents, lateral flow assay reagents, and molecular assay kits drive assay-specific supply chain and quality assurance requirements.

When viewed through test-type segmentation, the breadth from blood gases to infectious disease and molecular diagnostics affects instrument selection and clinician training, with cardiac markers and hematology requiring specialized assay robustness and coagulation testing demanding precise calibration and control across activated partial thromboplastin time, fibrinogen level, and prothrombin time and international normalized ratio assays. Infectious disease testing spans gastrointestinal, respiratory, and sexually transmitted infection panels, each influencing throughput needs and biosafety considerations. Sample-type segmentation, including blood, nasal and swab samples, saliva, and urine, informs collection device design, patient acceptability, and pre-analytical stability requirements. Technology segmentation differentiates biosensor electrochemical approaches, colorimetric platforms, immunoassays, lateral flow assays-spanning antibody, antigen, and multiplex formats-microfluidics, and PCR and molecular technologies, with each imparting trade-offs between sensitivity, specificity, cost, and operational complexity.

Portability options distinguish benchtop fixed analyzers from portable handheld devices, aligning device footprint with intended point of care settings. Mode of purchase segmentation separates over-the-counter accessibility from prescription-based dispensing, shaping labeling, user instructions, and post-market surveillance obligations. Application-driven segmentation-from chronic disease management to emergency and critical care, infectious disease diagnosis, occupational testing, oncology monitoring, and women's health-dictates performance thresholds and integration requirements with clinical care pathways. End-user segmentation that includes ambulatory care centers, diagnostic laboratories, free-standing emergency departments, home care, hospitals and clinics, and urgent care centers emphasizes differences in staffing, regulatory oversight, and capital acquisition processes. Finally, distribution channel segmentation across offline and online pathways, with offline methods such as direct sales, distributor and wholesale, and retail and pharmacy, impacts go-to-market strategies, margin structures, and customer support models. Taken together, these segmentation lenses provide a multifaceted view that guides product roadmaps, commercialization priorities, and lifecycle planning.

How geographic differences across the Americas, Europe Middle East and Africa, and Asia-Pacific shape procurement, regulation, and deployment of point of care diagnostics

Regional nuances significantly influence how point of care testing is designed, deployed, and reimbursed, with the Americas, Europe, Middle East and Africa, and Asia-Pacific each presenting distinct market drivers and operational considerations. In the Americas, health systems emphasize outpatient care optimization and chronic disease management, creating demand for devices and assays that support remote monitoring and rapid cardiovascular and metabolic testing in both clinic and home settings. Distribution networks in this region prioritize integrated supply chains and localized service support, which favors manufacturers that can demonstrate robust after-sales service and data interoperability with dominant electronic health records.

Europe, Middle East and Africa exhibit heterogeneity in regulatory regimes and healthcare infrastructure, with pockets of high regulatory rigor coexisting with areas where access barriers remain. This diversity requires adaptable product configurations and flexible pricing models. Interoperability standards and data privacy frameworks are especially influential in regulatory decision-making and clinical adoption in Europe, while capacity building and decentralized solutions are prioritized in many parts of the Middle East and Africa. In Asia-Pacific, rapid urbanization, expanding primary care networks, and high-volume public health screening initiatives drive demand for scalable, cost-effective point of care solutions. Regional manufacturing capabilities and supplier ecosystems in Asia-Pacific often accelerate product iteration cycles, and partnerships with local distributors are critical to achieve penetration across varied healthcare settings. Across all regions, reimbursement pathways, regulatory timelines, and customer training imperatives shape adoption velocity and product design choices.

Strategic competitive behaviors and platform-focused innovation that determine preparedness, resilience, and long-term differentiation within the diagnostic ecosystem

Competitive dynamics within the point of care testing landscape are characterized by strategic partnerships, platform differentiation, and a focus on integrated solutions that combine instruments, consumables, and software. Leading companies are prioritizing modular platform architectures that support multiple assay formats, enabling faster assay rollouts and improved lifetime value through recurring consumable demand. Concurrently, alliances with connectivity vendors and health IT integrators are becoming essential to deliver data-rich diagnostic results that plug into clinical workflows and population health initiatives.

Innovation strategies vary by firm, with some investing heavily in molecular and microfluidic technologies to expand the diagnostic menu, while others concentrate on low-cost lateral flow and biosensor technologies optimized for point-of-care ease of use. Service offerings, including field maintenance, calibration, and software updates, are being redefined as a competitive differentiator, and companies that can demonstrate rapid support turnaround and robust quality systems tend to secure larger institutional contracts. Supply chain resilience and localized manufacturing capabilities have also risen in strategic importance, prompting acquisitions and joint ventures to reduce exposure to global logistics disruptions. Finally, commercial models are shifting toward subscription and outcomes-based arrangements in select accounts, aligning vendor incentives with clinical performance and operational uptime.

Practical and prioritized strategic moves that companies should implement to secure adoption, supply resilience, and sustained commercial differentiation in diagnostics

To remain competitive and clinically relevant, industry leaders should pursue a set of actionable initiatives that align product development with operational realities and evolving care models. First, prioritize interoperability and user-centered software design so that devices integrate seamlessly into clinician workflows and electronic health records, thereby reducing friction at the point of adoption. Second, invest in modular platform strategies that allow rapid assay expansion and support multiple sample types, which increases flexibility for procurement teams and reduces the need for multiple device footprints.

Third, strengthen supply chain resilience through strategic regional sourcing, dual sourcing of critical components, and validated local assembly where feasible, which mitigates exposure to trade disruptions and tariff-driven cost pressures. Fourth, enhance post-market service offerings-particularly field maintenance and remote diagnostics-to preserve instrument uptime and protect clinical continuity. Fifth, adopt evidence-generation strategies that emphasize real-world performance, workflow impact, and patient-centric outcomes, thereby supporting payer discussions and clinical adoption. Finally, explore alternative commercial models, such as managed service agreements or outcome-linked contracts, to better align with healthcare purchasers' objectives and to create predictable revenue streams. Executing these actions with clear accountability and staged milestones will help firms convert technical capabilities into durable market advantage.

A transparent and reproducible research approach combining primary stakeholder interviews, rigorous secondary review, and data triangulation to validate conclusions

The research methodology underpinning this analysis integrates qualitative and quantitative approaches designed to ensure rigor, relevance, and reproducibility. Primary research consisted of in-depth interviews with clinicians, laboratory directors, procurement officers, and senior executives across device manufacturers and distributors to capture real-world use cases, procurement constraints, and unmet needs. These interviews were complemented by facility-level observations and validation of workflow integration points to translate clinical priorities into product requirements.

Secondary research included a systematic review of peer-reviewed clinical literature, regulatory guidance documents, industry standards for quality management and interoperability, and technical white papers describing assay and platform performance. Data triangulation techniques were employed to reconcile insights from diverse sources and to validate assumptions about operational behaviors and adoption barriers. The research also applied scenario analysis to assess supply chain risk and regulatory sensitivity, and key findings were stress-tested through expert panels to refine recommendations. Throughout, the methodology emphasized transparency, with audit trails linking conclusions to source materials and interview excerpts, ensuring that stakeholders can trace analytic judgments back to empirical evidence.

A conclusive synthesis emphasizing the balance between rapid diagnostic access, operational resilience, and rigorous quality controls to realize clinical impact

In conclusion, point of care testing is at an inflection point where technological maturity, changing care delivery models, and policy shifts are jointly redefining diagnostic pathways. The move toward decentralized diagnostics is supported by advances in assay chemistry, miniaturized instrumentation, and software connectivity, yet this transition also raises operational, regulatory, and supply chain challenges that require deliberate mitigation. Tariff actions, shifting procurement preferences, and regional regulatory heterogeneity add layers of complexity that stakeholders must address through resilient sourcing, adaptable product architectures, and robust evidence generation.

For manufacturers, the imperative is to deliver clinically rigorous, easy-to-use platforms that integrate seamlessly into workflows while offering sustainable service and supply models. For providers and payers, the focus should be on harnessing point of care capabilities to improve decision latency and patient experience without sacrificing quality controls. By aligning technology investments, commercial models, and implementation frameworks, stakeholders can realize the promise of point of care testing to deliver meaningful improvements in clinical care and operational efficiency.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Point of Care Testing Market, by Product

  • 8.1. Consumables Services & Software
    • 8.1.1. Consumables & Accessories
    • 8.1.2. Service Maintenance & Calibration
    • 8.1.3. Software & Connectivity
  • 8.2. Instruments & Analyzers
    • 8.2.1. Benchtop Analyzers
    • 8.2.2. Molecular Platforms
    • 8.2.3. Portable Analyzers
    • 8.2.4. Readers & Scanners
  • 8.3. Reagents & Assays
    • 8.3.1. Glucose Test Strips
    • 8.3.2. Hematology Reagents
    • 8.3.3. Immunoassay Reagents
    • 8.3.4. Lateral Flow Assay Reagents
    • 8.3.5. Molecular Assay Kits

9. Point of Care Testing Market, by Test Type

  • 9.1. Blood Gases
  • 9.2. Cardiac Markers
    • 9.2.1. B-type Natriuretic Peptide
    • 9.2.2. Troponin
  • 9.3. Comprehensive Metabolic Panel
  • 9.4. Drug Of Abuse Testing
  • 9.5. Hematology
    • 9.5.1. Coagulation Tests
      • 9.5.1.1. Activated Partial Thromboplastin Time
      • 9.5.1.2. Fibrinogen Level
      • 9.5.1.3. Prothrombin Time & International Normalized Ratio
    • 9.5.2. Complete Blood Count
  • 9.6. Infectious Disease
    • 9.6.1. Gastrointestinal Infection Tests
    • 9.6.2. Respiratory Infection Tests
    • 9.6.3. Sexually Transmitted Infection Tests
  • 9.7. Molecular Diagnostics
  • 9.8. Pregnancy & Fertility
  • 9.9. Urinalysis

10. Point of Care Testing Market, by Sample Type

  • 10.1. Blood
  • 10.2. Nasal & Swab Samples
  • 10.3. Saliva
  • 10.4. Urine

11. Point of Care Testing Market, by Technology

  • 11.1. Biosensor Electrochemical
  • 11.2. Colorimetric Platforms
  • 11.3. Immunoassay
  • 11.4. Lateral Flow Assays
    • 11.4.1. Antibody Tests
    • 11.4.2. Antigen Tests
    • 11.4.3. Multiplex Lateral Flow
  • 11.5. Microfluidics
  • 11.6. PCR And Molecular

12. Point of Care Testing Market, by Portability

  • 12.1. Benchtop Fixed Analyzers
  • 12.2. Portable Handheld Devices

13. Point of Care Testing Market, by Mode of Purchase

  • 13.1. Over-The-Counter Tests
  • 13.2. Prescription-Based Tests

14. Point of Care Testing Market, by Application

  • 14.1. Chronic Disease Management
  • 14.2. Emergency And Critical Care
  • 14.3. Infectious Disease Diagnosis
  • 14.4. Occupational And Workplace Testing
  • 14.5. Oncology Monitoring
  • 14.6. Women Health

15. Point of Care Testing Market, by End User

  • 15.1. Ambulatory Care Centers
  • 15.2. Diagnostic Laboratories
  • 15.3. Free-Standing Emergency Departments
  • 15.4. Home Care
  • 15.5. Hospitals & Clinics
  • 15.6. Urgent Care Centers

16. Point of Care Testing Market, by Distribution Channel

  • 16.1. Offline
    • 16.1.1. Direct Sales
    • 16.1.2. Distributor & Wholesale
    • 16.1.3. Retail & Pharmacy
  • 16.2. Online

17. Point of Care Testing Market, by Region

  • 17.1. Americas
    • 17.1.1. North America
    • 17.1.2. Latin America
  • 17.2. Europe, Middle East & Africa
    • 17.2.1. Europe
    • 17.2.2. Middle East
    • 17.2.3. Africa
  • 17.3. Asia-Pacific

18. Point of Care Testing Market, by Group

  • 18.1. ASEAN
  • 18.2. GCC
  • 18.3. European Union
  • 18.4. BRICS
  • 18.5. G7
  • 18.6. NATO

19. Point of Care Testing Market, by Country

  • 19.1. United States
  • 19.2. Canada
  • 19.3. Mexico
  • 19.4. Brazil
  • 19.5. United Kingdom
  • 19.6. Germany
  • 19.7. France
  • 19.8. Russia
  • 19.9. Italy
  • 19.10. Spain
  • 19.11. China
  • 19.12. India
  • 19.13. Japan
  • 19.14. Australia
  • 19.15. South Korea

20. United States Point of Care Testing Market

21. China Point of Care Testing Market

22. Competitive Landscape

  • 22.1. Market Concentration Analysis, 2025
    • 22.1.1. Concentration Ratio (CR)
    • 22.1.2. Herfindahl Hirschman Index (HHI)
  • 22.2. Recent Developments & Impact Analysis, 2025
  • 22.3. Product Portfolio Analysis, 2025
  • 22.4. Benchmarking Analysis, 2025
  • 22.5. Abaxis, Inc. by Zoetis Inc
  • 22.6. Abbott Laboratories
  • 22.7. AccuBioTech Co., Ltd.
  • 22.8. ACON Laboratories, Inc.
  • 22.9. Beckman Coulter
  • 22.10. Becton, Dickinson and Company
  • 22.11. Bio-Rad Laboratories, Inc.
  • 22.12. bioMerieux SA
  • 22.13. CardioGenics Holdings Inc.
  • 22.14. Chembio Diagnostic Systems, Inc. by Biosynex
  • 22.15. Danaher Corporation
  • 22.16. EKF Diagnostics Holdings
  • 22.17. F. Hoffmann-La Roche Ltd
  • 22.18. GE Healthcare Technologies, Inc.
  • 22.19. Medtronic Plc
  • 22.20. Nova Biomedical Corporation
  • 22.21. OraSure Technologies, Inc.
  • 22.22. Quidel Corporation
  • 22.23. Radiometer Medical ApS
  • 22.24. Randox Laboratories Ltd.
  • 22.25. Siemens Healthineers AG
  • 22.26. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL POINT OF CARE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL POINT OF CARE TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL POINT OF CARE TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. UNITED STATES POINT OF CARE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 17. CHINA POINT OF CARE TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL POINT OF CARE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SERVICE MAINTENANCE & CALIBRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SERVICE MAINTENANCE & CALIBRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SERVICE MAINTENANCE & CALIBRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SOFTWARE & CONNECTIVITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SOFTWARE & CONNECTIVITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SOFTWARE & CONNECTIVITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABLE ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABLE ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABLE ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY READERS & SCANNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY READERS & SCANNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY READERS & SCANNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GLUCOSE TEST STRIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GLUCOSE TEST STRIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GLUCOSE TEST STRIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR ASSAY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR ASSAY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR ASSAY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BLOOD GASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BLOOD GASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BLOOD GASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY B-TYPE NATRIURETIC PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY B-TYPE NATRIURETIC PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY B-TYPE NATRIURETIC PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COMPREHENSIVE METABOLIC PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COMPREHENSIVE METABOLIC PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COMPREHENSIVE METABOLIC PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DRUG OF ABUSE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DRUG OF ABUSE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DRUG OF ABUSE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ACTIVATED PARTIAL THROMBOPLASTIN TIME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ACTIVATED PARTIAL THROMBOPLASTIN TIME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ACTIVATED PARTIAL THROMBOPLASTIN TIME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY FIBRINOGEN LEVEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY FIBRINOGEN LEVEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY FIBRINOGEN LEVEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PROTHROMBIN TIME & INTERNATIONAL NORMALIZED RATIO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PROTHROMBIN TIME & INTERNATIONAL NORMALIZED RATIO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PROTHROMBIN TIME & INTERNATIONAL NORMALIZED RATIO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COMPLETE BLOOD COUNT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COMPLETE BLOOD COUNT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COMPLETE BLOOD COUNT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GASTROINTESTINAL INFECTION TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GASTROINTESTINAL INFECTION TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GASTROINTESTINAL INFECTION TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY RESPIRATORY INFECTION TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY RESPIRATORY INFECTION TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY RESPIRATORY INFECTION TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PREGNANCY & FERTILITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PREGNANCY & FERTILITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PREGNANCY & FERTILITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URINALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URINALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URINALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY NASAL & SWAB SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY NASAL & SWAB SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY NASAL & SWAB SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR ELECTROCHEMICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR ELECTROCHEMICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR ELECTROCHEMICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COLORIMETRIC PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COLORIMETRIC PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COLORIMETRIC PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ANTIBODY TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ANTIBODY TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ANTIBODY TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ANTIGEN TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ANTIGEN TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ANTIGEN TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MULTIPLEX LATERAL FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MULTIPLEX LATERAL FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MULTIPLEX LATERAL FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MICROFLUIDICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MICROFLUIDICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PCR AND MOLECULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PCR AND MOLECULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PCR AND MOLECULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BENCHTOP FIXED ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BENCHTOP FIXED ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BENCHTOP FIXED ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABLE HANDHELD DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABLE HANDHELD DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABLE HANDHELD DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OVER-THE-COUNTER TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OVER-THE-COUNTER TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OVER-THE-COUNTER TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PRESCRIPTION-BASED TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PRESCRIPTION-BASED TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PRESCRIPTION-BASED TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CHRONIC DISEASE MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CHRONIC DISEASE MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CHRONIC DISEASE MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY AND CRITICAL CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY AND CRITICAL CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY AND CRITICAL CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OCCUPATIONAL AND WORKPLACE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OCCUPATIONAL AND WORKPLACE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OCCUPATIONAL AND WORKPLACE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ONCOLOGY MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ONCOLOGY MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ONCOLOGY MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY WOMEN HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY WOMEN HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY WOMEN HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY FREE-STANDING EMERGENCY DEPARTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY FREE-STANDING EMERGENCY DEPARTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY FREE-STANDING EMERGENCY DEPARTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URGENT CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URGENT CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URGENT CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTOR & WHOLESALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTOR & WHOLESALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTOR & WHOLESALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY RETAIL & PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY RETAIL & PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY RETAIL & PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 225. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 226. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 227. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 228. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 229. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 230. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 232. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 234. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 235. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 238. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 239. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2018-2032 (USD MILLION)
  • TABLE 240. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 243. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 246. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 248. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 254. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 256. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 258. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2018-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 260. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 262. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 266. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 268. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 270. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 272. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 276. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2018-2032 (USD MILLION)
  • TABLE 278. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET